UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2021

Commission File Number 000-20181

 

SAPIENS INTERNATIONAL CORPORATION N.V.

(Translation of Registrant’s name into English)

 

Azrieli Center

26 Harokmim St.

Holon, 5885800

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒            Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 

 

 

CONTENTS

 

Exhibit No.   Title of Exhibit
99.1   Press release

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  

  Sapiens International Corporation N.V.
   
  By:  /s/ Roni Giladi
  Name:  Roni Giladi
  Title: Chief Financial Officer

 

Dated: February 24, 2021

 

2

 

 

EXHIBIT INDEX

 

The following exhibits are furnished as part of this Form 6-K:

 

Exhibit No.   Title of Exhibit
99.1   Press release

 

 

3

 

 

Exhibit 99.1

 

 

 

Sapiens Reports Q4 and Full Year 2020 Financial Results

 

Holon, Israel, February 25, 2021Sapiens International Corporation, (NASDAQ and TASE: SPNS), a leading global provider of software solutions for the insurance industry, and a member of the Formula Group (NASDAQ: FORTY and TASE: FORT), today announced its financial results for the fourth quarter and full year ended December 31, 2020.

 

Summary Results for Fourth Quarter 2020 (USD in millions, except per share data)

 

    GAAP               Non-GAAP        
    Q4 2020     Q4 2019     % Change         Q4 2020     Q4 2019     % Change  
Revenue   $ 101.7     $ 86.7       17.2 %       $ 102.9     $ 86.7       18.7 %
Gross Profit   $ 41.4     $ 34.9       18.4 %       $ 47.0     $ 38.4       22.5 %
Gross Margin     40.7 %     40.3 %     40 bps           45.7 %     44.3 %     140 bps  
Operating Income   $ 10.2     $ 10.2       -         $ 18.7     $ 14.3       30.1 %
Operating Margin     10.1 %     11.8 %     (170) bps           18.1 %     16.5 %     160 bps  
Net Income (*)   $ 8.3     $ 6.8       21.7 %       $ 14.5     $ 10.6       37.0 %
Diluted EPS   $ 0.15     $ 0.13       15.4 %       $ 0.27     $ 0.21       28.6 %

 

Summary Results for Full Year 2020 (USD in millions, except per share data)

 

    GAAP               Non-GAAP        
    2020     2019     % Change         2020     2019     % Change  
Revenue   $ 382.9     $ 325.7       17.6 %       $ 384.5     $ 325.7       18.1 %
Gross Profit   $ 156.0     $ 129.5       20.4 %       $ 172.9     $ 143.0       20.9 %
Gross Margin     40.7 %     39.8 %     90 bps           45.0 %     43.9 %     110 bps  
Operating Income   $ 45.0     $ 37.9       18.8 %       $ 67.9     $ 52.2       30.1 %
Operating Margin     11.8 %     11.6 %     20 bps           17.7 %     16.0 %     170 bps  
Net income (*)   $ 33.8     $ 26.2       28.7 %       $ 52.0     $ 38.9       33.6 %
Diluted EPS   $ 0.65     $ 0.52       25.0 %       $ 1.00     $ 0.77       29.9 %

 

(*) Attributable to Sapiens’ shareholders.

 

1

 

 

“The non-GAAP financial results Sapiens reported today demonstrate how well we are executing our strategy. Sapiens ended the year on a strong note with record fourth quarter revenue and a strong operating margin. Despite COVID-19, we crossed the $100 million-dollar-mark in quarterly Non-GAAP revenues, coming in at $103 million, 19% higher than last year. Non-GAAP Operating margin was 18.1%, 164 basis points, or 29% improvement from fourth quarter 2019, validating our operating leverage. For the full year, 2020 NON-GAAP revenue increased by 18% to $384 million and we delivered NON-GAAP operating margin of 17.7%. The global Sapiens team executed extremely well in 2020, and I want to thank everyone for their outstanding work in a year that presented unique challenges and required tremendous adaptability,” stated Roni Al-Dor, President and CEO of Sapiens.

 

“We have proven repeatedly that our “Land and Expand” strategy is an efficient and effective way to grow in the highly regulated and regionally diverse global insurance markets. In addition to our global advantage, we offer customers a one-stop-shop in P&C and Life, along with complimentary and digital solutions. With hundreds of customers around the world, Sapiens is making a significant impact with our broad portfolio of solutions and one-hand-to-shake business model. We entered 2021 with a positive momentum and are planning to leverage our recent acquisitions,” continued Mr. Al-Dor. Mr. Al-Dor concluded: “We are introducing 2021 guidance for NON-GAAP revenue in a range of $457 million to $463 million, and NON-GAAP operating margin in a range of 17.7% to 18.0%, reflecting the likelihood that certain cost savings related to COVID-19 diminish in the second half of 2021. With a focused growth strategy, global diversity and an even stronger balance sheet, Sapiens is well positioned for success and growth.”

 

 

Quarterly Results Conference Call

Management will host a conference call and webcast today, February 25, 2021 at 9:30 a.m. Eastern Time (4:30 p.m. in Israel) to review and discuss Sapiens’ results.

 

Please call the following numbers (at least 10 minutes before the scheduled time) to participate:

North America (toll-free): + 1-888- 642-5032; International: +972-3-918-0609; UK: 0-800-917-5108

 

The live webcast of the call can be viewed on Sapiens’ website at: https://www.sapiens.com/investor-relations/ir-events-presentations.

 

If you are unable to join live, a replay of the call will be accessible until March 4, 2020, as follows:

North America: +1-877-456-0009; International: +972-3-925-5900.

 

A recorded version of the webcast will also be available via the Sapiens website, for three months at the same location.

 

2

 

 

Non-GAAP Financial Measures

 

This press release contains the following non-GAAP financial measures: non-GAAP revenue, non-GAAP gross profit, non-GAAP operating income, non-GAAP net income attributed to Sapiens shareholders, non-GAAP basic and diluted earnings per share, Adjusted EBITDA and Adjusted Free Cash-Flow.

 

Sapiens believes that these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to Sapiens’ financial condition and results of operations. The Company’s management uses these non-GAAP measures to compare the Company’s performance to that of prior periods for trend analyses, for purposes of determining executive and senior management incentive compensation and for budgeting and planning purposes. These measures are used in financial reports prepared for management and in quarterly financial reports presented to the Company’s board of directors. The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends, and in comparing the Company’s financial measures with other software companies, many of which present similar non-GAAP financial measures to investors.

 

Non-GAAP financial measures consist of GAAP financial measures adjusted to exclude: Valuation adjustment on acquired deferred revenue, amortization of capitalized software development and other intangible assets, capitalization of software development, stock-based compensation, compensation related to acquisition and acquisition-related costs, restructuring and cost reduction costs, and tax adjustments related to non-GAAP adjustments.

 

Management of the Company does not consider these non-GAAP measures in isolation, or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements. In addition, they are subject to inherent limitations, as they reflect the exercise of judgment by management about which expenses and income are excluded or included in determining these non-GAAP financial measures.

 

To compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. Sapiens urges investors to review the reconciliation of its non-GAAP financial measures to the comparable GAAP financial measures, which it includes in press releases announcing quarterly financial results, including this press release, and not to rely on any single financial measure to evaluate the Company’s business.

 

Reconciliation tables of the most comparable GAAP financial measures to the non-GAAP financial measures used in this press release are included with the financial tables of this release.

 

The Company defines Adjusted EBITDA as net profit, adjusted for valuation adjustment on acquired deferred revenue, stock-based compensation expense, depreciation and amortization, capitalized of software development costs, compensation expenses related to acquisition and acquisition-related costs, restructuring and cost reduction costs, financial expense (income), provision for income taxes and other income (expenses). These amounts are often excluded by other companies to help investors understand the operational performance of their business.

 

The Company uses Adjusted EBITDA as a measurement of its operating performance, because it assists in comparing the operating performance on a consistent basis by removing the impact of certain non-cash and non-operating items. Adjusted EBITDA reflects an additional way of viewing aspects of the operations that the Company believes, when viewed with the GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provide a more complete understanding of factors and trends affecting its business. The Company uses Adjusted Free Cash-Flow as a measurement of its operating performance, and reconciles cash-flow from operating activities to Adjusted Free Cash-Flow, while reducing the amounts for capitalization of software development costs and capital expenditures. The Company adds back cash payments made for former acquisitions in respect of  future performance targets and retention criteria as determined upon acquisition date of the respective acquired company, which were included in the cash-flow from operating activities. We believe that Adjusted Free Cash-Flow is useful in evaluating our business, because Adjusted Free Cash-Flow reflects the cash surplus available to fund the expansion of our business.

 

3

 

 

About Sapiens

 

Sapiens International Corporation empowers insurers to succeed in an evolving industry. The company offers digital software platforms, solutions and services for the property and casualty, life, pension and annuity, reinsurance, financial and compliance, workers’ compensation and financial markets. With more than 35 years of experience delivering to more than 600 organizations globally, Sapiens has a proven ability to satisfy customers’ core, data and digital requirements. For more information: www.sapiens.com.

 

Forward Looking Statements

 

Certain matters discussed in this prospectus supplement, the accompanying prospectus and the other documents we have filed with the SEC that are incorporated herein and therein by reference are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our beliefs, assumptions and expectations, as well as information currently available to us. Such forward-looking statements may be identified by the use of the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “will,” “plan” and similar expressions. Such statements reflect our current views with respect to future events and are subject to certain risks and uncertainties. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: the COVID-19 (coronavirus) pandemic, which may last longer than expected and materially adversely affect our results of operations; the degree of our success in our plans to leverage our global footprint to grow our sales; the degree of our success in integrating the companies that we have acquired through the implementation of our M&A growth strategy; the lengthy development cycles for our solutions, which may frustrate our ability to realize revenues and/or profits from our potential new solutions; our lengthy and complex sales cycles, which do not always result in the realization of revenues; the degree of our success in retaining our existing customers or competing effectively for greater market share; difficulties in successfully planning and managing changes in the size of our operations; the frequency of the long-term, large, complex projects that we perform that involve complex estimates of project costs and profit margins, which sometimes change mid-stream; the challenges and potential liability that heightened privacy laws and regulations pose to our business; occasional disputes with clients, which may adversely impact our results of operations and our reputation; various intellectual property issues related to our business; potential unanticipated product vulnerabilities or cybersecurity breaches of our or our customers’ systems; risks related to the insurance industry in which our clients operate; risks associated with our global sales and operations, such as changes in regulatory requirements, wide-spread viruses and epidemics like the recent novel coronavirus outbreak, or fluctuations in currency exchange rates; and risks related to our principal location in Israel and our status as a Cayman Islands company.

 

While we believe such forward-looking statements are based on reasonable assumptions, should one or more of the underlying assumptions prove incorrect, or these risks or uncertainties materialize, our actual results may differ materially from those expressed or implied by the forward-looking statements. Please read the risks discussed under the heading “Risk Factors” in this prospectus supplement and in the accompanying prospectus, and under the heading “Risk Factors” in our most recent Annual Report on Form 20-F and in our other filings with the SEC that are incorporated by reference in this prospectus supplement and the accompanying prospectus, in order to review conditions that we believe could cause actual results to differ materially from those contemplated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus supplement, to conform these statements to actual results or to changes in our expectations.

 

Investors and Media Contact

Sapiens

Daphna Golden

Vice President, Head of Investor Relations

Email: ir@sapiens.com

 

Hayden IR
Brett Mass
Managing Partner
Phone: +1 646-536-7331
Email: Brett.Masss@HaydenIR.com

 

4

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

U.S. dollars in thousands (except per share amounts)

 

   

Three months ended

December 31

   

Year ended

December 31,

 
    2020     2019     2020     2019  
    (unaudited)     (unaudited)     (unaudited)     (unaudited)  
                         
Revenue     101,661       86,715       382,903       325,674  
Cost of revenue     60,288       51,782       226,929       196,153  
                                 
Gross profit     41,373       34,933       155,974       129,521  
                                 
Operating expenses:                                
Research and development, net     11,129       10,233       41,358       37,378  
Selling, marketing, general and administrative     20,019       14,477       69,613       54,274  
Total operating expenses     31,148       24,710       110,971       91,652  
                                 
Operating income     10,225       10,223       45,003       37,869  
                               
Financial and other expenses, net     1,212       1,019       3,805       2,768  
Taxes on income     611       2,260       7,041       8,610  
                                 
Net income     8,402       6,944       34,157       26,491  
                                 
Attributable to non-controlling interest     83       110       382       244  
                                 
Net income attributable to Sapiens’ shareholders     8,319       6,834       33,775       26,247  
                                 
Basic earnings per share     0.16       0.14       0.67       0.53  
                                 
Diluted earnings per share     0.15       0.13       0.65       0.52  
                                 
Weighted average number of shares outstanding used to compute basic earnings per share (in thousands)     53,715       50,109       51,208       50,031  
                                 
Weighted average number of shares outstanding used to compute diluted earnings per share (in thousands)     54,541       51,009       52,159       50,653  

 

5

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED NON-GAAP STATEMENTS OF INCOME

U.S. dollars in thousands (except per share amounts)

 

    Three months ended     Year ended  
    December 31     December 31,  
    2020     2019     2020     2019  
    (unaudited)     (unaudited)     (unaudited)     (unaudited)  
                         
Revenue     102,936       86,715       384,501       325,674  
Cost of revenue     55,892       48,313       211,560       182,662  
                                 
Gross profit     47,044       38,402       172,941       143,012  
                                 
Operating expenses:                                
Research and development, net     12,733       11,395       47,156       43,043  
Selling, marketing, general and administrative     15,645       12,662       57,863       47,763  
Total operating expenses     28,378       24,057       105,019       90,806  
                                 
Operating income     18,666       14,345       67,922       52,206  
                                 
Financial and other expenses, net     1,212       1,019       3,805       2,768  
Taxes on income     2,910       2,663       11,776       10,298  
                                 
Net income     14,544       10,663       52,341       39,140  
                                 
Attributable to non-controlling interest     83       110       382       244  
                                 
Net income attributable to Sapiens’ shareholders     14,461       10,553       51,959       38,896  
                                 
Basic earnings per share     0.27       0.21       1.01       0.78  
                                 
Diluted earnings per share     0.27       0.21       1.00       0.77  
                                 
Weighted average number of shares outstanding used to compute basic earnings per share (in thousands)     53,715       50,109       51,208       50,031  
                                 
Weighted average number of shares outstanding used to compute diluted earnings per share (in thousands)     54,541       51,009       52,159       50,653  

 

6

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND SUBSIDIARIES

 

RECONCILIATION OF GAAP TO NON-GAAP RESULTS

U.S. dollars in thousands (except per share amounts)

 

    Three months ended     Year ended  
    December 31,     December 31,  
    2020     2019     2020     2019  
    (unaudited)     (unaudited)     (unaudited)     (unaudited)  
                         
GAAP revenue     101,661       86,715       382,903       325,674  
Valuation adjustment on acquired deferred revenue     1,275       -       1,598       -  
Non-GAAP revenue     102,936       86,715       384,501       325,674  
                                 
GAAP gross profit     41,373       34,933       155,974       129,521  
Revenue adjustment     1,275       -       1,598       -  
Amortization of capitalized software     1,931       1,499       6,558       5,668  
Amortization of other intangible assets     2,465       1,970       8,811       7,823  
Non-GAAP gross profit     47,044       38,402       172,941       143,012  
                                 
GAAP operating income     10,225       10,223       45,003       37,869  
Gross profit adjustments     5,671       3,469       16,967       13,491  
Capitalization of software development     (1,604 )     (1,162 )     (5,798 )     (5,665 )
Amortization of other intangible assets     1,204       563       3,316       2,177  
Stock-based compensation     1,240       282       3,987       1,405  
Acquisition-related costs *)     1,930       970       4,447       2,929  
Non-GAAP operating income     18,666       14,345       67,922       52,206  
                                 
GAAP net income attributable to Sapiens’ shareholders     8,319       6,834       33,775       26,247  
Operating income adjustments     8,441       4,122       22,919       14,337  
Taxes on income     (2,299 )     (403 )     (4,735 )     (1,688 )
Non-GAAP net income attributable to Sapiens’ shareholders     14,461       10,553       51,959       38,896  

 

(*) Acquisition-related costs pertain to charges on behalf of M&A agreements related to future performance targets and retention criteria, as well as third-party services, such as, tax, accounting and legal rendered until the acquisition date.

 

7

 

 

Summary of NON-GAAP Financial Information
U.S. dollars in thousands (except per share amounts)

 

    Q4 2020     Q3 2020     Q2 2020     Q1 2020     Q4 2019  
                               
Revenues     102,936       97,968       93,063       90,534       86,715  
Gross profit     47,044       44,206       41,900       39,791       38,402  
Operating income     18,666       17,859       16,783       14,614       14,345  
Net income to Sapiens’ shareholders     14,461       13,746       13,340       10,412       10,553  
Adjusted EBITDA     20,032       19,010       17,854       15,724       15,271  
                                         
Basic earnings per share     0.27       0.27       0.27       0.21       0.21  
Diluted earnings per share     0.27       0.27       0.26       0.20       0.21  

 

Non-GAAP Revenues by Geographic Breakdown
U.S. dollars in thousands

 

    Q4 2020     Q3 2020     Q2 2020     Q1 2020     Q4 2019  
                               
North America     47,303       49,979       46,610       44,567       41,787  
Europe     49,225       42,394       41,030       40,232       37,504  
Rest of the world     6,408       5,595       5,423       5,735       7,424  
                                         
Total     102,936       97,968       93,063       90,534       86,715  

 

Adjusted Free Cash-Flow
U.S. dollars in thousands

 

    Q4 2020     Q3 2020     Q2 2020     Q1 2020     Q4 2019  
                               
Cash-flow from operating activities     21,030       16,705       14,761       5,759       21,429  
Increase in capitalized software development costs     (1,604 )     (1,506 )     (1,251 )     (1,437 )     (1,162 )
Capital expenditures     (725 )     (963 )     (393 )     (552 )     (2,456 )
Free cash-flow     18,701       14,236       13,117       3,770       17,811  
                                         
Cash payments attributed to acquisition-related
costs(*) (**)
    2,363       242       1,562       737       200  
                                         
Adjusted free cash-flow     21,064       14,478       14,679       4,507       18,011  

 

(*) Included in cash-flow from operating activities

 

(**) Acquisition-related payments pertain to payments on behalf of M&A agreements related to future performance targets and retention criteria, as well as third-party services, such as, tax, accounting and legal rendered until the acquisition date.


 

8

 

 

Adjusted EBITDA Calculation
U.S. dollars in thousands

 

    Three months ended     Year ended  
    December 31,     December 31,  
    2020     2019     2020     2019  
                         
GAAP operating profit     10,225       10,223       45,003       37,869  
                                 
Non-GAAP adjustments:                                
Valuation adjustment on acquired deferred revenue     1,275       -       1,598       -  
Amortization of capitalized software     1,931       1,499       6,558       5,668  
Amortization of other intangible assets     3,669       2,533       12,127       10,000  
Capitalization of software development     (1,604 )     (1,162 )     (5,798 )     (5,665 )
Stock-based compensation     1,240       282       3,987       1,405  
Compensation related to acquisition and acquisition-related costs     1,930       970       4,447       2,929  
                                 
Non-GAAP operating profit     18,666       14,345       67,922       52,206  
                                 
Depreciation     1,366       926       4,698       3,470  
                                 
Adjusted EBITDA     20,032       15,271       72,620       55,676  

 

9

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

 

    December 31,     December 31,  
    2020     2019  
    (unaudited)     (unaudited)  
             
ASSETS            
             
CURRENT ASSETS            
Cash and cash equivalents     152,561       66,295  
Short-term bank deposit     30,000       -  
Trade receivables, net and unbilled receivables     65,409       50,221  
Investment in restricted deposit     -       22,890  
Other receivables and prepaid expenses     19,388       7,817  
                 
Total current assets     267,358       147,223  
                 
LONG-TERM ASSETS                
Property and equipment, net     16,970       16,601  
Severance pay fund     6,582       5,106  
Goodwill and intangible assets, net     363,597       228,691  
Operating lease right-of-use assets     54,390       49,539  
Other long-term assets     5,264       5,261  
                 
Total long-term assets     446,803       305,198  
                 
TOTAL ASSETS     714,161       452,421  
                 
LIABILITIES AND EQUITY                
                 
CURRENT LIABILITIES                
Trade payables     5,389       5,107  
Current maturities of Series B Debentures     19,796       9,898  
Accrued expenses and other liabilities     75,119       60,574  
Current maturities of operating lease liabilities     9,924       8,312  
Deferred revenue     34,548       21,021  
                 
Total current liabilities     144,776       104,912  
                 
LONG-TERM LIABILITIES                
Series B Debentures, net of current maturities     98,676       58,850  
Deferred tax liabilities     16,010       5,082  
Other long-term liabilities     12,129       8,321  
Long-term operating lease liabilities     48,773       43,394  
Accrued severance pay     9,586       6,364  
                 
Total long-term liabilities     185,174       122,011  
                 
REDEEMABLE NON-CONTROLLING INTEREST     517       -  
                 
EQUITY     383,694       225,498  
                 
TOTAL LIABILITIES AND EQUITY     714,161       452,421  

 

10

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONSOLIDATED STATEMENT OF CASH FLOW
U.S. dollars in thousands

 

    For the twelve months ended December 31,  
    2020     2019  
    (unaudited)     (unaudited)  
Cash flows from operating activities:            
Net income     34,157       26,491  
Reconciliation of net income to net cash provided by operating activities:                
Impairment of right of use asset     351       -  
Depreciation and amortization     23,383       19,138  
Accretion of discount on Series B Debentures     134       171  
Capital loss (gain) from sale of property and equipment     44       (40 )
Stock-based compensation related to options issued to employees     3,987       1,405  
                 
Net changes in operating assets and liabilities, net of amount acquired:                
Trade receivables, net and unbilled receivables     (5,168 )     10,514  
Deferred tax assets, net     (16 )     (6,441 )
Other operating assets     (2,049 )     6,726  
Trade payables     (1,344 )     (1,476 )
Other operating liabilities     1,435       6,667  
Deferred revenues     2,992       2,747  
Accrued severance pay, net     349       255  
                 
Net cash provided by operating activities     58,255       66,157  
                 
Cash flows from investing activities:                
Purchase of property and equipment     (2,633 )     (11,474 )
Investment in deposit     (30,397 )     (1,119 )
Proceeds from sale of property and equipment     12       834  
Proceeds from (investment in) restricted deposit used for completed acquisition     22,890       (22,890 )
Payments for business acquisitions, net of cash acquired     (95,866 )     (1,554 )
Capitalized software development costs     (5,798 )     (5,665 )
Acquisition of intellectual property     (2,810 )     -  
                 
Net cash used in investing activities     (114,602 )     (41,868 )
                 
Cash flows from financing activities:                
Proceeds from employee stock options exercised     5,050       780  
Distribution of dividend     (7,044 )     (11,009 )
Repayment of Series B Debenture     (9,898 )     (9,898 )
Proceeds from issuance of Series B Debentures     60,346       -  
Receipt of short-term loan     20,000       -  
Repayment of loan     (20,000 )     (4 )
Payment of contingent considerations     (538 )     (374 )
Acquisition of minority interests     (147 )     -  
Dividend to non-controlling interest     -       (149 )
Repayment of loan of acquired subsidiary     (13,186 )     -  
Proceeds from issuance of ordinary shares, net of issuance expenses     108,737       -  
                 
Net cash provided by (used in) financing activities     143,320       (20,654 )
                 
Effect of exchange rate changes on cash and cash equivalents     (707 )     (1,968 )
                 
Increase in cash and cash equivalents     86,266       1,667  
Cash and cash equivalents at the beginning of period     66,295       64,628  
                 
Cash and cash equivalents at the end of period     152,561       66,295  

 

11

 

  

Debentures Covenants

 

As of December 31, 2020, Sapiens was in compliance with all of its financial covenants under the indenture for the Series B Debentures, based on having achieved the following in its consolidated financial results:

 

Covenant 1

 

Target shareholders’ equity (excluding minority interest): above $120 million.
     
Actual shareholders’ equity (excluding minority interest) equal to $382 million.

 

Covenant 2

 

Target ratio of net financial indebtedness to net capitalization (in each case, as defined under the indenture for the Company’s Series B Debentures) below 65%.
     
  Actual ratio of net financial indebtedness to net capitalization equal to (9.75)%.
     

Covenant 3

 

Target ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is below 5.5.
     
Actual ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is equal to (0.47).

 

 

12